soul trial semaglutide cardiovascular outcomes oral semaglutide offers meaningful cardiovascular benefits - SOUL trial semaglutideppt semaglutide SOUL Trial: Oral Semaglutide Demonstrates Significant Cardiovascular Benefits

SOUL trial semaglutideresults The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) has provided compelling evidence regarding the cardiovascular efficacy of oral semaglutide, a groundbreaking medication for individuals with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both. This phase 3b cardiovascular outcomes trial was designed to assess the cardiovascular efficacy of oral semaglutide and has yielded significant results, found a lower risk of cardiovascular events with oral semaglutide compared to placebo.

The SOUL trial is a large-scale, randomized, double-blind, parallel-group, placebo-controlled CV outcomes trial that randomized 9650 participants with type 2 diabetes. The primary objective was to determine if oral semaglutide could reduce the incidence of major adverse cardiovascular events (MACE).2024年10月21日—Over the course of the trial, which began in 2019 and completed in 2021,oral semaglutide demonstrated a 14% reduction in the risk of MACE... The trial achieved its primary endpoint, demonstrating a significant reduction in risk2025年6月23日—Conclusion: InSOUL, theCVbenefits of oral sema appeared more pronounced with higher A1c levels at baseline but were consistent across various ....

Key Findings and Efficacy:

A consistent and impactful finding from the SOUL trial is the 14% reduction in the risk of MACE observed with oral semaglutide versus placebo.Oral Semaglutide and Cardiovascular Outcomes This reduction encompasses several critical cardiovascular endpoints, including cardiovascular death, non-fatal heart attacks, and non-fatal strokes. Specifically, oral semaglutide improved each of the composite measures, contributing to a more robust cardiovascular profile for patients. Further analysis revealed that oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14%.

The study also explored the impact of concomitant treatments.2025年10月31日—SOULis a randomized, double‐blind, parallel‐group, placebo‐controlledCV outcomes trialcomparing oralsemaglutide(14 mg once daily) with placebo. Notably, oral semaglutide reduced major adverse cardiovascular event outcomes independently of concomitant SGLT2i treatment, and this combination appeared to be safe2025年3月29日—TheSOUL trialshowed that in patients with T2DM and ASCVD, CKD, or both, use of oralsemaglutidewas associated with a significantly lower risk .... This finding suggests that oral semaglutide offers cardiovascular benefits that are not solely dependent on other commonly used diabetes medications like SGLT2 inhibitors.2025年3月29日—Oral semaglutide (Rybelsus; Novo Nordisk) taken once dailycut the risk of cardiovascular mortality, nonfatal MI, or nonfatal stroke in the trial by 14%. This underscores the versatile cardiovascular advantages of semaglutide.

Further prespecified analyses of the SOUL Randomized Trial indicated that the CV benefits of oral semaglutide appeared more pronounced with higher HbA1c levels at baseline but remained consistent across various patient subgroups. This suggests that oral semaglutide reduces cardiovascular risk in T2D patients, regardless of their baseline glycemic control within the studied population.

Safety and Tolerability:

In terms of safety, the SOUL trial reported a manageable safety profileEffects of oral semaglutide on heart failure outcomes in people .... The incidence of serious adverse events was 47Effects of oral semaglutide on cardiovascular outcomes in ....9% in the oral semaglutide group and 50.3% in the placebo groupSemaglutide Cardiovascular Outcomes Trial - SOUL. This indicates that oral semaglutide was well-tolerated by the participants, with a safety profile comparable to placebo in this high-risk population.

Impact on Heart Failure:

Beyond the primary MACE endpoints, the SOUL trial also aimed to evaluate the effect of oral semaglutide versus placebo on heart failure (HF) outcomes. While the full extent of these findings is being explored, preliminary results and related research suggest a positive impact on heart failure outcomes, further bolstering the cardiovascular benefits of this semaglutide formulation.

Expert Endorsements and Future Implications:

The results of the SOUL trial have garnered significant attention within the medical community. Researchers like DK McGuire and N Marx have been instrumental in presenting and analyzing these findings, highlighting the cardiovascular benefits beyond glycemic control that semaglutide offers.2025年3月30日—Oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular ... The SOUL trial results indicate oral semaglutide reduces MACE risk, with semaglutide reduces MACEs primarily by a reduction in CV-related deaths, offering a new paradigm in managing cardiovascular risk in individuals with type 2 diabetes作者：I Jialal·2025·被引用次数：1—In this largetrial, oralsemaglutidetherapy resulted in a 14% relative risk reduction in major ASCVD events compared to placebo in T2DM patents with ASCVD, ....

The publication of SOUL trial semaglutide results in esteemed scientific journals, including potential appearances in the SOUL trial NEJM or similar high-impact publications, is anticipated to further solidify its place in clinical practice.Oral Semaglutide Reduces Cardiovascular Events by 14% ... The SOUL trial summary of these findings emphasizes that oral semaglutide offers meaningful cardiovascular benefits and represents a significant advancement in the treatment of patients with elevated cardiovascular risk.

In conclusion, the SOUL trial has definitively established oral semaglutide as a valuable therapeutic option for reducing cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.Effects of oral semaglutide on cardiovascular outcomes in ... Its efficacy in reducing MACE, coupled with a favorable safety profile, positions oral semaglutide as a crucial tool in comprehensive cardiovascular risk management.